Cervical Dystonia Market is Growing at a CAGR of 7.30 % during Forecast period 2023 - 2032

Pune, India, 2023 /MRFR Press Release/- Market Research Future published a half-cooked research report on Global cervical dystonia market.

Market Highlights

Cervical dystonia is a neurological movement disorder associated with involuntary movement of neck. It is also known as spasmodic torticollis. The major driving factor for the market are increasing prevalence of Parkinson’s diseases, technological advances and unmet need for the treatment of cervical dystonia.  As per study it was estimated that women are more prone to get this diseases. While on other hand high cost associated with treatment may restrain the growth of the market.The global Cervical Dystonia Market is expected to be valued at USD 0.377074 billion by 2032, growing at an 7.30 % CAGR during forecast 2023-2032

On regional basis, global cervical dystonia market is segmented into North America, Europe, Asia Pacific and Middle East and Africa. The market is dominated by North America. Due to developed infrastructure, governmental initiatives, increasing demand for the better treatment of cervical dystonia are the major driving factor in North America. Beside this increasing aging population in Canada has provided fuel for the growth of North America cervical dystonia market. Europe and Asia Pacific share nearly similar market but in coming future Asia Pacific will lead the market due to continuous development and increasing need of better treatment of cervical dystonia. Due to a huge population base of Asia Pacific due to India and China has provided a base for the development of this market in Asia Pacific region. Middle East and Africa contribute least in the market due to less development in medical sector.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cervical Dystonia Market Research Report

Segmentation:
Global cervical dystonia market has been segmented on the basis of type which includes torticollis, retrocollis, laterocollis and others.  On the basis of treatment they are segmented into oral therapy, intravenous, surgery and other. On the basis of end user they are segmented into hospital, clinics and other. On the basis of type torticollis is the occurring type of this disease which is followed by laterocollis.

Competitive Analysis

The major key player for the global cervical dystonia market are ALLERGAN (Ireland), Solstice Neurosciences LLC, Ipsen Biopharmaceuticals Inc. (France), Merz Inc (US), Addex Therapeutics (Switzerland) and many other.
Due to increasing prevalence of cervical dystonia globally many of the companies are in the race to introduce better oral treatment for cervical dystonia. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.
Revance Therapeutics Inc. in 2016 initiated a Phase II study of RT002 for the treatment of cervical dystonia. Company is expecting to introduce this drug in market very soon.
ALLERGAN has introduced BOTOX® (onabotulinumtoxinA) for treatment of cervical dystonia. It is prescribed to 16 and older people suffering from cervical dystonia. It is an intramuscular drug.
Solstice Neurosciences LLC has introduced MYOBLOC (rimabotulinumtoxinB), which was the first FDA-approved treatment for cervical dystonia. It is used for the treatment of cervical dystonia in adults to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
Ipsen Biopharmaceuticals Inc. a French company introduced Dysport® (abobotulinumtoxinA) for the treatment of adults with cervical dystonia.